Current DAVDP Recommendation

• Single, adequately powered 48-week “equivalence” design clinical trial

  • Submission of 24-week interim results for regulatory review
  • Submission of 48-week results as phase IV commitment

• Supportive PK and safety data

Previous slide

Next slide

Back to first slide

View graphic version